MDWD
MediWound Ltd. [MDWD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MDWD Stock Summary
Top 10 Correlated ETFs
MDWD
Top 10 Correlated Stocks
MDWD
In the News
MDWD Financial details
Company Rating
-
Market Cap
151.77M
Income
-6.72M
Revenue
18.69M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
100
Optionable
No
Shortable
Yes
Earnings
28 May 2024
P/E
-9.26
Forward P/E
-
PEG
1.15
P/S
4.61
P/B
3.48
P/C
-
P/FCF
-11.19
Quick Ratio
5.88
Current Ratio
6.31
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.77
EPS next Y
-
EPS next Q
-
EPS this Y
-80.92%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-10.08%
Revenue Q/Q
11.77%
EPS Q/Q
-20.83%
-
-
-
-
SMA20
5.02%
SMA50
-1.22%
SMA100
0.49%
Inst Own
-
Inst Trans
-
ROA
-19%
ROE
-44%
ROC
-0.16%
Gross Margin
44%
Oper. Margin
-38%
Profit Margin
-50%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.1-17.25
52W High
+8.35%
52W Low
+163.14%
RSI
48.99
Rel Volume
1.02
Avg Volume
66.21K
Volume
67.58K
Perf Week
-1.07%
Perf Month
0.77%
Perf Quarter
-10.01%
Perf Half Y
-4.41%
-
-
-
-
Beta
0.926
-
-
Volatility
0.21%, 0.63%
Prev Close
-0.22%
Price
18.42
Change
-1.66%
Company Profile
- Volume Average 66.21K
- Market Capitalization 151.77M
- Employee 100
- CEO Mr. Ofer Gonen B.Sc.
- Headquarters Yavne,IL
- IPO Date 2014-03-20
-
Website
https://www.mediwound.com 
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
